Tango Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, disclosing financial and operational information for the third quarter of fiscal year 2026.

Key Highlights

  • Share count: As of November 2, 2026, the registrant had 169,455,160 shares of common stock, $0.001 par value per share, outstanding.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
  • No product revenue: The filing states the company "has no products approved for commercial sale, have not generated any revenue from product sales and may never become profitable."
  • Continued net losses: The company disclosed it "has incurred significant net losses since our inception and anticipates that we will continue to incur losses for the foreseeable future."
  • API supply concentration: According to the filing, "an affiliate of WuXi AppTec is the sole source of API for all of our clinical-stage product candidates."
  • Capital needs: The filing states the company "will need to raise substantial additional funding" and that inability to do so could force delays, reductions, or elimination of product development programs.

Tango Therapeutics Outlines Key Risks in Third Quarter 2026 Disclosure

Tango Therapeutics, Inc. (NASDAQ:TNGX), a precision oncology company headquartered at 201 Brookline Ave., Suite 901, Boston, MA 02215, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing covers Part I financial information and Part II other information, including legal proceedings, risk factors, and unregistered sales of equity securities.

The company described itself as a precision oncology company "with a limited operating history" focused on "the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers." The filing notes that this area is "a rapidly evolving area of science, and the approach we are taking to develop drugs is novel and may never lead to approved or marketable products." The company further disclosed that certain programs remain in preclinical development and "may never advance to clinical development."

Among the operational risks disclosed, the company identified its reliance on a limited number of third-party manufacturers as a significant concern. Specifically, the filing notes that WuXi AppTec "has been the subject of proposed Congressional legislation that, if enacted, could materially restrict our ability to conduct business with, and obtain API from, WuXi AppTec." The filing also cautions that raising additional capital "may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates."

What Was Disclosed

Tango Therapeutics filed its Q3 2026 quarterly report disclosing 169,455,160 shares outstanding as of November 2, 2026, its status as a non-accelerated filer and smaller reporting company, ongoing net losses, no approved products or product revenue, and material risks related to API supply concentration and capital requirements.